Vor Biopharma (VOR) News Today $33.90 -1.80 (-5.03%) As of 02:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VOR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Vor Biopharma (NYSE:VOR) Major Shareholder Sells $54,866.00 in StockOctober 4 at 6:34 AM | insidertrades.comVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 1,400 SharesOctober 3, 2025 | marketbeat.comReprogrammed Interchange Llc Sells 7,901 Shares of Vor Biopharma (NYSE:VOR) StockOctober 3, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 32,451 SharesOctober 3, 2025 | marketbeat.comVor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 3, 2025 | globenewswire.comVor Biopharma Inc. $VOR Shares Acquired by Goldman Sachs Group Inc.October 1, 2025 | marketbeat.comShort Interest in Vor Biopharma Inc. (NASDAQ:VOR) Drops By 94.4%September 30, 2025 | marketbeat.comVor Biopharma (VOR) Price Target Increased by 2,942.55% to 36.46September 30, 2025 | msn.comVor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025September 29, 2025 | globenewswire.comComparing Prime Medicine (NASDAQ:PRME) and Vor Biopharma (NASDAQ:VOR)September 28, 2025 | americanbankingnews.comVor Biopharma (NYSE:VOR) Raised to "Buy" at Stifel NicolausSeptember 26, 2025 | americanbankingnews.comVor Biopharma (NYSE:VOR) and Prime Medicine (NASDAQ:PRME) Critical SurveySeptember 26, 2025 | americanbankingnews.comVor Biopharma stock drops after filing to register warrant sharesSeptember 25, 2025 | za.investing.comVor Biopharma Shares Slide Following Warrant Registration FilingSeptember 25, 2025 | msn.comVor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease PromiseSeptember 25, 2025 | seekingalpha.comVor Biopharma registers 51M shares for resale linked to RemeGen deal and PIPE financingSeptember 24, 2025 | msn.comVor Biopharma upgraded to Buy at Stifel on telitacicept prospectsSeptember 24, 2025 | msn.comStifel Nicolaus Upgrades Vor Biopharma (NYSE:VOR) to BuySeptember 24, 2025 | marketbeat.comVor Biopharma Shares Rise After Appointment of Navid Khan as Medical Affairs ChiefSeptember 23, 2025 | marketwatch.comVor Bio Appoints Navid Z. Khan, Ph.D.September 23, 2025 | globenewswire.comReprogrammed Interchange Llc Sells 447,278 Shares of Vor Biopharma (NYSE:VOR) StockSeptember 20, 2025 | marketbeat.comVor Biopharma (NASDAQ:VOR) Trading Down 7.2% - Here's What HappenedSeptember 20, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Stock Price Down 8.6% After Insider SellingSeptember 20, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 447,278 SharesSeptember 19, 2025 | marketbeat.comVor Biopharma trading halted, news pendingSeptember 19, 2025 | msn.comVor Biopharma trading halted on Thursday, news pendingSeptember 19, 2025 | msn.comVor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Moderate Buy" by BrokeragesSeptember 18, 2025 | marketbeat.comResults of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual MeetingSeptember 17, 2025 | prnewswire.comVor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEMSeptember 17, 2025 | globenewswire.comReprogrammed Interchange Llc Sells 284,805 Shares of Vor Biopharma (NYSE:VOR) StockSeptember 16, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Major Shareholder Sells $525,000.00 in StockSeptember 16, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Major Shareholder Sells $656,000.00 in StockSeptember 16, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 284,805 SharesSeptember 16, 2025 | insidertrades.comVor Biopharma (NASDAQ:VOR) Upgraded by Zacks Research to "Hold" RatingSeptember 14, 2025 | marketbeat.comInsider Selling: Vor Biopharma (NYSE:VOR) Major Shareholder Sells 464,421 Shares of StockSeptember 12, 2025 | marketbeat.comReprogrammed Interchange Llc Sells 350,000 Shares of Vor Biopharma (NYSE:VOR) StockSeptember 12, 2025 | marketbeat.comReprogrammed Interchange Llc Sells 449,226 Shares of Vor Biopharma (NYSE:VOR) StockSeptember 12, 2025 | marketbeat.comVor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation ForumSeptember 12, 2025 | globenewswire.comInsider Selling: Vor Biopharma (NYSE:VOR) Major Shareholder Sells 350,000 Shares of StockSeptember 11, 2025 | insidertrades.comWe Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth CarefullySeptember 7, 2025 | finance.yahoo.comOMERS ADMINISTRATION Corp Takes Position in Vor Biopharma Inc. $VORSeptember 7, 2025 | marketbeat.comVor Bio Appoints Adi Osovsky, S.J.D. as General CounselSeptember 2, 2025 | globenewswire.comInsider Selling: Vor Biopharma (NYSE:VOR) Major Shareholder Sells 611,647 Shares of StockAugust 30, 2025 | insidertrades.comVor Biopharma (NASDAQ:VOR) Shares Down 3.8% - Time to Sell?August 30, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 284,190 SharesAugust 28, 2025 | insidertrades.comVor Biopharma shares rise after collaborator’s IgAN therapy meets Phase 3 endpointAugust 28, 2025 | msn.comVor Biopharma stock rises after collaborator's IgAN drug hits endpointAugust 27, 2025 | investing.comVor Biopharma Files Prospectus for $119.7M Stock SaleAugust 27, 2025 | tipranks.comTelitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA NephropathyAugust 27, 2025 | globenewswire.comVor Bio to Participate in Upcoming Investor ConferencesAugust 26, 2025 | globenewswire.com Get Vor Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VOR Media Mentions By Week VOR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VOR News Sentiment▼0.510.21▲Average Manufacturing News Sentiment VOR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VOR Articles This Week▼93▲VOR Articles Average Week Get the Latest News and Ratings for VOR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Vor Biopharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies UPB News Today PGEN News Today CRON News Today VALN News Today NBTX News Today SYRE News Today DNA News Today RLAY News Today SANA News Today BGM News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VOR) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vor Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vor Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
